View in EDS PDF Full Text

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Saved in:
Bibliographic Details
Title: A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Authors: Goldstein LJ; Fox Chase Cancer Center, Philadelphia, PA, USA. lori.goldstein@fccc.edu., Zhao F; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Wang M; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Swaby RF; Fox Chase Cancer Center, Philadelphia, PA, USA.; Merck Pharmaceuticals, North Wales, PA, USA., Sparano JA; West Chester Medical Center, Valhalla, NY, USA., Meropol NJ; Fox Chase Cancer Center, Philadelphia, PA, USA.; University Hospitals Case Medical Center, Cleveland, OH, USA., Bhalla KN; MD Anderson Cancer Center, Houston, TX, USA.; Georgia Regents University NCORP, Augusta, Georgia., Pellegrino CM; West Chester Medical Center, Valhalla, NY, USA., Katherine Alpaugh R; Fox Chase Cancer Center, Philadelphia, PA, USA., Falkson CI; University of Alabama, Birmingham, AL, England, UK., Klein P; Beth Israel Medical Center, New York, USA.; St. Vincent's Comp. Cancer Center, New York, USA., Sledge GW; Stanford University, Stanford, CA, USA.; Indiana University Cancer Center, Indianapolis, IN, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Sep; Vol. 165 (2), pp. 375-382. Date of Electronic Publication: 2017 Jun 16.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28623430
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Goldstein+LJ%22">Goldstein LJ</searchLink>; Fox Chase Cancer Center, Philadelphia, PA, USA. lori.goldstein@fccc.edu.<br /><searchLink fieldCode="AU" term="%22Zhao+F%22">Zhao F</searchLink>; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Swaby+RF%22">Swaby RF</searchLink>; Fox Chase Cancer Center, Philadelphia, PA, USA.; Merck Pharmaceuticals, North Wales, PA, USA.<br /><searchLink fieldCode="AU" term="%22Sparano+JA%22">Sparano JA</searchLink>; West Chester Medical Center, Valhalla, NY, USA.<br /><searchLink fieldCode="AU" term="%22Meropol+NJ%22">Meropol NJ</searchLink>; Fox Chase Cancer Center, Philadelphia, PA, USA.; University Hospitals Case Medical Center, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Bhalla+KN%22">Bhalla KN</searchLink>; MD Anderson Cancer Center, Houston, TX, USA.; Georgia Regents University NCORP, Augusta, Georgia.<br /><searchLink fieldCode="AU" term="%22Pellegrino+CM%22">Pellegrino CM</searchLink>; West Chester Medical Center, Valhalla, NY, USA.<br /><searchLink fieldCode="AU" term="%22Katherine+Alpaugh+R%22">Katherine Alpaugh R</searchLink>; Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Falkson+CI%22">Falkson CI</searchLink>; University of Alabama, Birmingham, AL, England, UK.<br /><searchLink fieldCode="AU" term="%22Klein+P%22">Klein P</searchLink>; Beth Israel Medical Center, New York, USA.; St. Vincent's Comp. Cancer Center, New York, USA.<br /><searchLink fieldCode="AU" term="%22Sledge+GW%22">Sledge GW</searchLink>; Stanford University, Stanford, CA, USA.; Indiana University Cancer Center, Indianapolis, IN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2017 Sep; Vol. 165 (2), pp. 375-382. <i>Date of Electronic Publication: </i>2017 Jun 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28623430
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-017-4310-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 375
    Titles:
      – TitleFull: A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Goldstein LJ
      – PersonEntity:
          Name:
            NameFull: Zhao F
      – PersonEntity:
          Name:
            NameFull: Wang M
      – PersonEntity:
          Name:
            NameFull: Swaby RF
      – PersonEntity:
          Name:
            NameFull: Sparano JA
      – PersonEntity:
          Name:
            NameFull: Meropol NJ
      – PersonEntity:
          Name:
            NameFull: Bhalla KN
      – PersonEntity:
          Name:
            NameFull: Pellegrino CM
      – PersonEntity:
          Name:
            NameFull: Katherine Alpaugh R
      – PersonEntity:
          Name:
            NameFull: Falkson CI
      – PersonEntity:
          Name:
            NameFull: Klein P
      – PersonEntity:
          Name:
            NameFull: Sledge GW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2017 Sep
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 165
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1